Cervical carcinoma remains a health issue for women worldwide. Cervical cytology screening is the current method for early detection, and the NCCN Cervical Cancer Screening Clinical Practice Guidelines in Oncology provide direction for evaluating and managing this process, including clarified and revised recommendations on screening techniques and intervals and follow-up of abnormal screening results, including colposcopy. Human papillomavirus (HPV) DNA testing for primary cervical cancer has been approved by the FDA, and HPV DNA testing for high-risk virus types can also be used as a component of both primary screening and workup of abnormal cytology results. Colposcopy, along with colposcopically directed biopsies, has become the primary method for evaluating women with abnormal cervical cytologies. Special considerations for colposcopy performed during pregnancy are also discussed.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
The Stanford Cancer Center is an international leader in cancer research and patient care. The mission of the Stanford Clinical Cancer Program is to provide comprehensive care through multidisciplinary collaboration and integrated services; advance cancer therapies through clinical research; and train future leaders in the treatment of patients with cancer. The collaborative approach to cancer research and treatment is a hallmark of this program.One hundred and sixty faculty members participate in cancer care and clinical research with over 250 active clinical trials. Research on the fundamentals of cancer is conducted in the Center for Molecular and Genetic Medicine and the Center for Clinical Sciences Research. Stanford researchers and physicians have led the way in developing many of the current state-of-the-art radiology, antibody, and biologic therapies that are used to treat cancers. The Cancer Center also encompasses basic population-based research into the causes and consequences of cancer and supports 16 interdisciplinary disease-related programs.Steven A. Leibel, MD, is the Medical Director of the Stanford Cancer Center and a professor of Radiation Oncology. Irv Weissman, MD (not pictured), is the Director, and Beverly Mitchell, MD (not pictured), is the Deputy Director of the Stanford Cancer Center.